PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
December 19, 2024
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, December 18, 2024 – PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David